Patent extension policy for paediatric indications

Richard Nelson, Carrie McAdam-Marx, Megan Evans, Robert Ward, Benjamin Campbell, Diana Brixner and Joanne Lafleur

Applied Health Economics and Health Policy, 2011, vol. 9, issue 3, 181 pages

Abstract: Makers of the branded drugs evaluated were given market exclusivity extensions for conducting studies of their medications in children. The costs found in this study are just a small portion of the total paid, which include those born by other payers. Whether the benefits of this policy outweigh these costs is an open question, but these results suggest that the costs to Medicaid and thus taxpayers are substantial. Copyright Adis Data Information BV 2011

Date: 2011
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://hdl.handle.net/10.2165/11539060-000000000-00000 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:aphecp:v:9:y:2011:i:3:p:171-181

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40258

DOI: 10.2165/11539060-000000000-00000

Access Statistics for this article

Applied Health Economics and Health Policy is currently edited by Timothy Wrightson

More articles in Applied Health Economics and Health Policy from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().